@northoftheborder

Actually, there are a few things that bother me.

First, I've heard this before about how indefinitely taking lutamide and ADT slows resistance in some patients. What some guys talk about this? This is real true? Apalutamide was released in 2018, and encalutamide in 2012. Who did the math?

Second, people constantly write on this forum about guys who have been living with this for 20 years or more (even with high Gleason scores). So, the question arises: 2026 - 20 = 2006 (year), and doublet and triplet therapy only began in 2012. Are these guys living 20 years on ADT alone?

Third, risk balance. Yes, North, you told me that if you stop ADT, a hormone-dependent patient will very quickly go on the offensive, and if the lesion was extensive, stopping ADT is like getting shot in the temple. But doesn't the risk of resilience outweigh this? Intuitively, even without being a doctor, I understand one thing: risks must be taken, because an unmade choice can lead to even greater risks.

What do you think?